Acrivon TherapeuticsACRV
ACRV
About: Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Employees: 61
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
19% more capital invested
Capital invested by funds: $136M [Q2] → $162M (+$25.4M) [Q3]
0% more funds holding
Funds holding: 54 [Q2] → 54 (+0) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
1.49% less ownership
Funds ownership: 76.0% [Q2] → 74.52% (-1.49%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
253%
upside
Avg. target
$25
293%
upside
High target
$27
333%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
BMO Capital Etzer Darout 29% 1-year accuracy 12 / 41 met price target | 333%upside $27 | Outperform Maintained | 14 Nov 2024 |
HC Wainwright & Co. Emily Bodnar 15% 1-year accuracy 23 / 150 met price target | 253%upside $22 | Buy Reiterated | 14 Nov 2024 |
Financial journalist opinion
Positive
Seeking Alpha
1 week ago
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis
Acrivon Therapeutics is developing a targeted oncology therapy with a companion proteomics-based signature, showing promising activity in their lead compound for certain patients with gynecologic cancers. The pipeline updates indicate progress in clinical trials, enhancing the potential for successful outcomes in targeted cancer treatments. Financially, Acrivon is well-positioned with sufficient funding to advance its pipeline, though risks remain inherent in biotech investments.
Neutral
GlobeNewsWire
2 months ago
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today announced that the company approved a grant of equity awards under its 2023 Inducement Plan to certain employees. The equity awards were granted in the form of stock options and have a grant date of October 15, 2024.
Neutral
GlobeNewsWire
2 months ago
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
- First patient dosed two quarters ahead of original timelines in Acrivon Phase 1 study to assess safety and tolerability of ACR-2316
Positive
Seeking Alpha
3 months ago
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects
Acrivon Therapeutics shows promise in precision oncology with its AP3 platform and positive Phase 2 data for ACR-368, indicating potential for significant stock growth. Acrivon's robust pipeline, including the accelerated development of ACR-2316, and a strong cash position, highlight its commitment to advancing innovative cancer therapies. Despite being pre-revenue and operating at a loss due to high R&D expenses, ACRV maintains a healthy cash balance, crucial for ongoing operations and development.
Neutral
GlobeNewsWire
3 months ago
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
WATERTOWN, Mass., Sept. 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today presented additional positive clinical data at ESMO from the ongoing registrational intent, multicenter Phase 2 trial of ACR-368 in patients with locally advanced or metastatic, recurrent endometrial cancer. The company has also disclosed that the Investigational New Drug (IND) application for its next clinical candidate, ACR-2316, has been cleared by the FDA with initial clinical sites now activated, and first-in-human dosing for the Phase 1 study expected in the fourth quarter of 2024.
Negative
Zacks Investment Research
4 months ago
Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?
Here is how Acrivon Therapeutics, Inc. (ACRV) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
6 months ago
Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year?
Here is how Acrivon Therapeutics, Inc. (ACRV) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
Positive
Seeking Alpha
6 months ago
Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?
Acrivon Therapeutics, Inc. is an oncology-focused biotech using a multi-targeted panel to identify patients for clinical trials. Acrivon Therapeutics is focused on ACR-368, a CHK1/2 inhibitor, with promising results in gynecologic cancers using their OncoSignature platform. Financially stable with $112.1 million in assets, Acrivon Therapeutics CRV has the potential for accelerated approval and future pipeline expansion.
Positive
Zacks Investment Research
6 months ago
Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year?
Here is how Acrivon Therapeutics, Inc. (ACRV) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
6 months ago
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Wednesday, June 5, 2024 at 9:30 a.m. ET at the Jefferies Global Healthcare Conference in New York.
Charts implemented using Lightweight Charts™